Anticipating the Future of the COVID-19 Pandemic: Insights into the Emergence of SARS-CoV-2 Variant JN.1 and Its Projected Impact on Older Adults

Overview

Journal Geroscience

Specialty Geriatrics

Date 2024 Jan 10

PMID 38198026

Authors

Jorge Quarleri

M Victoria Delpino

Veronica Galvan

Affiliations

Soon will be listed here.

Citing Articles

Real-Time PCR-Based Test as a Research Tool for the Retrospective Detection and Identification of SARS-CoV-2 Variants of Concern in a Sample.

Makarova V, Shelkov A, Iliukhina A, Azizyan V, Dolzhikova I, Vasilieva E Int J Mol Sci. 2025; 26(5).

PMID: 40076414 PMC: 11898500. DOI: 10.3390/ijms26051786.

Fortifying defenses: Tactical safety protocols for COVID-19 sub-variant JN.1 in healthcare and laboratory settings.

Sheereen S, Manva M, Sheereen S J Family Med Prim Care. 2025; 14(1):78-84.

PMID: 39989551 PMC: 11844938. DOI: 10.4103/jfmpc.jfmpc_170_24.

The JN.1 variant of COVID-19: immune evasion, transmissibility, and implications for global health.

Naveed Siddiqui A, Musharaf I, Gulumbe B Ther Adv Infect Dis. 2025; 12:20499361251314763.

PMID: 39896217 PMC: 11783492. DOI: 10.1177/20499361251314763.

Evaluation of the Content Validity of the COVID-19 Symptoms Daily Diary.

Dine J, Guan Y, Milien M, Ervin C, Byrne D, Brown M Patient Relat Outcome Meas. 2025; 16():37-53.

PMID: 39839844 PMC: 11748756. DOI: 10.2147/PROM.S488914.

Emerging SARS-CoV-2 Variants in Uganda in the Era of COVID-19 Vaccination.

Bbosa N, Kiiza R, Ssekagiri A, Namagembe H, Nabirye S, Kabuuka D Viruses. 2025; 16(12).

PMID: 39772170 PMC: 11680199. DOI: 10.3390/v16121860.

References

Quarleri J, Galvan V, Delpino M . Omicron variant of the SARS-CoV-2: a quest to define the consequences of its high mutational load. Geroscience. 2021; 44(1):53-56. PMC: 8683309. DOI: 10.1007/s11357-021-00500-4. View

Viana R, Moyo S, Amoako D, Tegally H, Scheepers C, Althaus C . Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022; 603(7902):679-686. PMC: 8942855. DOI: 10.1038/s41586-022-04411-y. View

Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E . Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat Med. 2022; 28(9):1785-1790. PMC: 9499863. DOI: 10.1038/s41591-022-01911-2. View

Accorsi E, Britton A, Fleming-Dutra K, Smith Z, Shang N, Derado G . Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA. 2022; 327(7):639-651. PMC: 8848203. DOI: 10.1001/jama.2022.0470. View

Kuhlmann C, Mayer C, Claassen M, Maponga T, Burgers W, Keeton R . Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. Lancet. 2022; 399(10325):625-626. PMC: 8765759. DOI: 10.1016/S0140-6736(22)00090-3. View

Lin D, Xu Y, Gu Y, Zeng D, Sunny S, Moore Z . Durability of Bivalent Boosters against Omicron Subvariants. N Engl J Med. 2023; 388(19):1818-1820. PMC: 10120009. DOI: 10.1056/NEJMc2302462. View

Rahman M, Kamigaki T, Thandar M, Haruyama R, Yan F, Shibamura-Fujiogi M . Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis. BMJ Open. 2023; 13(12):e076892. DOI: 10.1136/bmjopen-2023-076892. View

Chen Q, Qin S, Zhou H, Deng Y, Shi P, Zhao H . Competitive fitness and homologous recombination of SARS-CoV-2 variants of concern. J Med Virol. 2023; 95(12):e29278. DOI: 10.1002/jmv.29278. View

Miller J, Hachmann N, Collier A, Lasrado N, Mazurek C, Patio R . Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1. N Engl J Med. 2023; 388(7):662-664. PMC: 9878581. DOI: 10.1056/NEJMc2214314. View

10.

Barnes C, Jette C, Abernathy M, Dam K, Esswein S, Gristick H . SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature. 2020; 588(7839):682-687. PMC: 8092461. DOI: 10.1038/s41586-020-2852-1. View

11.

Gruell H, Vanshylla K, Weber T, Barnes C, Kreer C, Klein F . Antibody-mediated neutralization of SARS-CoV-2. Immunity. 2022; 55(6):925-944. PMC: 9118976. DOI: 10.1016/j.immuni.2022.05.005. View

12.

Cao Y, Jian F, Yu Y, Song W, Yisimayi A, Wang J . Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature. 2022; 614(7948):521-529. PMC: 9931576. DOI: 10.1038/s41586-022-05644-7. View

13.

Park Y, Pinto D, Walls A, Liu Z, De Marco A, Benigni F . Imprinted antibody responses against SARS-CoV-2 Omicron sublineages. Science. 2022; 378(6620):619-627. DOI: 10.1126/science.adc9127. View

14.

Harris E . One in 5 Males Worldwide Has High-Risk Genital HPV. JAMA. 2023; 330(11):1029. DOI: 10.1001/jama.2023.16108. View

15.

Meo S, Meo A, Klonoff D . Omicron new variant BA.2.86 (Pirola): Epidemiological, biological, and clinical characteristics - a global data-based analysis. Eur Rev Med Pharmacol Sci. 2023; 27(19):9470-9476. DOI: 10.26355/eurrev_202310_33975. View

16.

Wannigama D, Amarasiri M, Phattharapornjaroen P, Hurst C, Modchang C, Chadsuthi S . Tracing the new SARS-CoV-2 variant BA.2.86 in the community through wastewater surveillance in Bangkok, Thailand. Lancet Infect Dis. 2023; 23(11):e464-e466. DOI: 10.1016/S1473-3099(23)00620-5. View

17.

Wang Q, Guo Y, Liu L, Schwanz L, Li Z, Nair M . Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike. Nature. 2023; 624(7992):639-644. DOI: 10.1038/s41586-023-06750-w. View

18.

Uriu K, Ito J, Kosugi Y, Tanaka Y, Mugita Y, Guo Z . Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant. Lancet Infect Dis. 2023; 23(11):e460-e461. DOI: 10.1016/S1473-3099(23)00575-3. View

19.

Sheward D, Yang Y, Westerberg M, Oling S, Muschiol S, Sato K . Sensitivity of the SARS-CoV-2 BA.2.86 variant to prevailing neutralising antibody responses. Lancet Infect Dis. 2023; 23(11):e462-e463. DOI: 10.1016/S1473-3099(23)00588-1. View

20.

Levin E, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S . Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N Engl J Med. 2021; 385(24):e84. PMC: 8522797. DOI: 10.1056/NEJMoa2114583. View